Influence of nitric oxide and angiotensin II on renal involvement in hypertension

Hypertension

Volumn 29, Issue 1 II, 1997, Pages 188-193

  Frohlich, Edward D ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

angiotensin converting enzyme inhibition; arteriolar disease; endothelium; glomerular disease; hydrochlorothiazide; L arginine; L NAME; nephrosclerosis; nitric oxide

Indexed keywords

ANGIOTENSIN; ARGININE; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; NITRIC OXIDE; DIURETIC AGENT; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; THIAZIDE DIURETIC AGENT;

AGED; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; GLOMERULOPATHY; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FAILURE; MALE; NEPHROSCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR RESISTANCE; ANIMAL; CHRONIC KIDNEY FAILURE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; KIDNEY; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

AGING; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; DIURETICS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, INBRED SHR; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 0030636346     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.29.1.188     Document Type: Article

References (60)

1. Corcoran AC, Page IH. The effect of angiotonin on renal blood flow and glomerular filtration. Am J Physiol. 1940;130:335-339.
2. Taylor RD, Page IH, Corcoran AC. A hormonal neurogenic vasopressor mechanism. Arch Intern Med. 1951;88:1-8.
3. Page IH, Corcoran AC. Hypertension and the problem of vascular homeostasis. Circulation. 1952;6:286-292.
4. Masson GMC, Plahl G, Corcoran AC, Page IH. Accelerated hypertensive vascular disease from saline and renin in nephrectomized dogs. Arch Pathol. 1953;55:85-97.
5. Masson GMC, DelGreco F, Corcoran AC, Page IH. Acute diffuse vascular disease elicited by renin in rats pretreated with cortisone. Arch Pathol. 1953;56:23-35.
6. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke and coronary heart disease. II: Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-838.
7. Thijs L, Fagard R, Lijnen P, Staessen J, Van Hoot R, Amery A. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens. 1992;10:1103-1109.
8. Blyth WB, Maddux FW. Hypertension as a causative diagnosis of patients entering end-stage renal disease programs in the United States from 1980 to 1986. Am J Kidney Dis. 1991;18:33-37.
9. US Renal Data Systems. 1995 Annual Data Report. National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases, III: incidence and causes of treated ESRD. Am J Kidney Dis. 1995;26:S39-S50.
10. Rodicio JL. Does antihypertensive treatment protect the kidney in essential hypertension? J Hypertens. 1996;14(suppl 2):S69-S76.
11. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephros: a potentially adverse response to renal ablation. Am J Physiol. 1981;241:F85-F93.
12. Dworkin LD, Feiner HO. Glomerular injury in uninephrectomized spontaneously hypertensive rats: a consequence of glomerular capillary hypertension. J Clin Invest. 1986;77:797-805.
13. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the tale of hemodynamically mediated glomerular disease in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652-659.
14. 1 adrenergic receptor responsiveness. Am J Physiol. 1991;260: R889-R893.
15. Uchino K, Nishikimi T, Frohlich ED. Alpha-1 adrenergic receptor blockade reduces afferent and efferent glomerular arteriolar resistances in SHR. Am J Physiol. 1991;261:R576-R580.
16. Isshiki T, Pegram BL, Frohlich ED. Hemodynamic comparison of diltiazem and TA-3090 in spontaneously hypertensive and normal Wistar-Kyoto rats. Am J Cardiol. 1988;62:79-84.
17. Isshiki T, Nishikimi T, Uchino K, Kardon MB, Frohlich ED. Diltiazem reduces glomerular pressure in spontaneously hypertensive rats. Cardiovasc Drugs Ther. 1992;6:91-92.
18. 1-adrenoceptor inhibition on intrarenal hemodynamics in SHR. Am J Physiol. 1994;266:R1437-R1442.
19. Komatsu K, Numabe A, Ono Y, Frohlich ED. Hydrochlorothiazide increases efferent glomerular arteriolar resistance in spontaneously hypertensive rats. J Cardiovasc Pharmacol Ther. 1996; 1:57-64.
20. Feld LB, Van Liew JB, Galaske RG, Boylan JW. Selectivity of renal injury and proteinuria in the spontaneously-hypertensive rat. Kidney Int. 1977;12:332-343.
21. Feld LG, Cachero S, Van Liew JB, Zamlanski-Tucker M, Moble B. Enalapril and renal injury in spontaneously hypertensive rats. Hypertension. 1990;16:544-554.
22. Frohlich ED. State of the Art: The First Irvine H. Page Lecture: the mosaic of hypertension: past, present, and future. J Hypertens. 1988; 6:S2-S11.
23. Frohlich ED. Left ventricular hypertrophy: dissociation of structural and functional effects by therapy. Cellular and Molecular Mechanisms in Hypertension: Implication for Pathogenesis and Treatment. Cox RH, ed. New York, NY: Plenum Press; 1991:175-190.
24. Frohlich, ED, Tarazi, RC. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? Am J Cardiol. 1979;44: 959-963.
25. Frohlich ED. Overview of hemodynamic and non-hemodynamic factors associated with LVH. J Mol Cell Cardiol. 1989;21:3-10.
26. Komatsu K, Frohlich ED, Ono H, Ono Y, Numabe A, Willis GW. Glomerular dynamics and morphology of aged SHR. Hypertension. 1995;25:207-213.
27. Ono H, Ono Y, Frohlich ED. Nitric oxide synthase inhibition in spontaneously hypertensive rats. Hypertension. 1995;26:249-255.
28. Furchgott RF. Role of endothelium in responses of vascular smooth muscle. Circ Res. 1983;53:557-573.
29. Vanhoutte PM, Rubanyi GM, Miller VM, Houston DS. Modulation of vascular smooth muscle contraction by the endothelium. Annu Rev Physiol. 1986;48:307-320.
30. Raij L. Nitric oxide and the kidney. Circulation. 1993;87(suppl V): V-26-V-29.
31. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
32. Lüscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension. 1986;8:344-348.
33. Sunano S, Itoh H, Isogai N, Osugi S, Yamanoto K, Shimamura K. Effects of antihypertensive treatment on endothelial structure and endotheliurn-dependent relaxation in aorta of stroke-prone spontaneously hypertensive rats. J Vasc Med Biol. 1993;4:235-242.
34. Fujii K, Ohmori S, Tominaga M, Abe I, Takata Y, Ohya Y, Kobayashi K, Fujishima M. Age-related changes in endothelium-dependent hyperpolarization in the rat mescuteric artery. Am J Physiol. 1993;265:H509-H516.
35. Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int. 1995;48:20-32.
36. Ono H, Ono Y, Frohlich ED. ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension. 1996;27:176-183.
37. Ono Y, Ono H, Frohlich ED. Hydrochlorothiazide exacerbates nitric oxide blockades nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens. 1996;14:823-828.
38. Ono H, Ono Y, Frohlich ED. L-arginine reverses severe nephrosclerosis in aged spontaneously hypertensive rats (SHR). Hypertension. 1996;28:537. Abstract.
39. Tarazi RC, Frohlich RC, Dustan HP. Long-term thiazide therapy in hypertension. Evidence for persistent alteration of plasma volume and renin activity. Circulation. 1970;41:709-717.
40. Horiba N, Nomura K, Shizume K. Exogenous and locally synthesized angiotensin II and glomerulea cell functions. Hypertension. 1990;15: 190-197.
41. Cook JL, Chen L, Bhandaru S, Bakris GL, Re RN. The use of antisense oligonucleotides to establish autocrine angiotensin growth effects in human neuro blastonea and mesangial cells. Antisense Res Dev. 1992;2:199-210.
42. Anderson PW, Doy S, Hsueh WA. Angiotensin II causes mesangial cell hypertrophy. Hypertension. 1993;21:166-172.
43. Bakris GL, Re RN. Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol. 1993;264: F937-F942.
44. Mulrow PJ. The intrarenal renin-angiotensin system. Curr Opin Nephrol Hypertens. 1993;2:41-44.
45. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization: beyond nitric oxide and cyclic GMP. Circulation. 1995;92: 3337-3349.
46. Fitzgibbon WR, Jaffa AA, Mayfield RK, Ploth DW. Role of kinins in the renal response to enalaprilat in normotensive and hypertensive rats Hypertension. 1996;27:235-244.
47. Numabe A, Uehara Y, Hirawa N, Takeda S, Yagi S. Effects of thiazide diuretics on vascular eicosenoid system of spontaneously hypertensive rats. J Hypertens. 1989;7:493-499.
48. Richard V, Hogie M, Clozel M, Loffler BM, Thuilliez C. In vivo evidence of an endothelium induced vasopressor tone after inhibition of nitric oxide synthase in rats. Circulation. 1995;91:771-775.
49. Li JM, Fanton RA, Cutler BS, Dobson JG Jr.: Adenosine enhances nitric oxide production by vascular endothelial cells. Am J Physiol. 1995;269:C519-C523.
50. Fujita K. Matsumura Y. Miyazaki Y. Takaoka M. Morimoto S. Role of endothelin-1 in hypertension induced by long-term inhibition of nitric oxide synthase. Eur J Pharmacol. 1995;280:311-316.
51. Qiu C, Engels K, Samsell L, Baylis C. Renal effects of acute amino acid infusion in hypertension induced by chronic nitric oxide blockade Hypertension. 1995;25:61-66.
52. Tsakada M, Yamazaki Y, Koizumi A. Changes in nitric oxide synthase in the cerebellum during development and aging of C57BL/16 mice Tohoku J Exp Med. 1995;176:69-74.
53. Gerhard M, Roddy MA, Creager SJ, Creager MA. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension. 1996;27:849-853.
54. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation. 1993;88:2541-2547.
55. Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, Cannon RO, III. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation. 1994;90:35-41.
56. Treasure CB, Klein JC, Vita JA, Manoukianu SV, Renwick GH, Selwyn AP, Ganz P, Alexander RW. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary artery resistance vessels. Circulation. 1993;87:86-93.
57. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelia-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-1474.
58. Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of increased availability of-endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation. 1993;87:1475-1481.
59. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO III. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995; 91:1732-1738.
60. Page IH. The mosaic theory of arterial hypertension: its interpretation. Perspect Biol Med. 1967;10:325-333.